(Reuters) – CSL, an Australian biotech company (OTC) stated on Thursday that it had committed to the agreement regarding production of approximately 50 million doses AstraZeneca’s COVID-19 vaccination vaccine through 2022.
After a media report claimed that Vaxzevria’s British-made vaccine would no longer be made in Australia because of high demand. Pfizer (NYSE,) Moderna (NASDAQ) [nL4N2R91XR]
Moderna and Pfizer have established market dominance using the mRNA-based COVID-19 vaccination technology to combat the pandemic.
CSL stated in a short statement that 20 million doses of drug have been manufactured and that it was expected to complete the remainder by the beginning of next year.
Sydney welcomes fully vaccinated people back to cafes and restaurants after almost four months lockdown.
Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.